Today, the Mesothelioma Applied Research Foundation announced that it will fund three research projects in the field of mesothelioma for a total investment of $300,000…
(877) 363-6376
HELPLINE
A new approach of anti-PD1 immunotherapy (atezolizumab) combined with bevacizumab (an agent that blocks the growth of new blood vessels therefore limiting the supply of…
Join us next Tuesday, June 9 at 2:00 PM ET for a Meet the Mesothelioma Experts (MTME) interview with Dr. Zachary Horne on Facebook Live.…
A phase 2 immunotherapy clinical trial combining durvalumab, an immunotherapy drug, with standard treatment of Alimta (pemetrexed)/cisplatin has shown promising overall survival results. The study enrolled 55 patients and…
In 2016, the Mesothelioma Applied Research Foundation funded a grant to Antonio Giordano, MD, PhD, director and founder of the Sbarro Health Research Organization at Temple University, to investigate how silencing…